# A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome

> **NCT00251511** · PHASE2 · TERMINATED · sponsor: **Veeda Oncology** · enrollment: 60 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Arsenic Trioxide

## Key facts

- **NCT ID:** NCT00251511
- **Lead sponsor:** Veeda Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-08
- **Primary completion:** 2006-01
- **Final completion:** 2007-05
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** Sponsor terminated trial
- **Last updated:** 2012-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00251511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00251511, "A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00251511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*